{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"6 months"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"}]}],"title":"12 months"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"}],"units":"Participants"}],"description":"Proportion of participants achieving progression-free survival. Measured from date of initiation of treatment (Day 1) to the earliest occurrence of any of the following events: documented disease progression, or death from any cause. Patients who are alive and progression-free will be censored at the date of last documented progression-free status.","groups":[{"description":"Fenofibrate orally daily for each 28 day cycle, per study protocol.\n\nFenofibrate: Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance \\< 50 mL/min will receive a reduced dose of 54 mg orally daily.","id":"OG000","title":"Fenofibrate Therapy"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months, 12 months","title":"Proportion of Participants Achieving Progression-Free Survival","type":"SECONDARY","unitOfMeasure":"participants"}